Dual targeting of Phosphoinositide 3-Kinase (PI3K) and histone deacetylase 6 (HDAC6) in cancer
Phosphoinositide 3-kinases (PI3Ks) and histone deacetylase 6 (HDAC6) have been widely studied as promising therapeutic targets in cancer. Both play key roles in maintaining cellular homeostasis, and their dysregulation is closely linked to oncogenesis. Consequently, several dual PI3K/HDAC6 inhibitors have been developed as potential anticancer agents. This review explores the cellular and molecular functions of PI3K and HDAC6, their involvement in cancer progression, and the structural and pharmacological properties of dual-targeting inhibitors. Additionally, we discuss future perspectives for designing clinically effective dual PI3K/HDAC6 inhibitors.
Authors
- Sharifah Aminah Syed Mohamad (ORCID: https://orcid.org/0000-0002-6161-7915)
- Sami Hamdoun
- Nafees Ahemad (ORCID: https://orcid.org/0000-0002-5164-1970)
Institutions
- Monash University Malaysia (MY)
- UCSI University (MY)
- Universiti Teknologi MARA (MY)
Publication Details
- Journal
- Biochemical Pharmacology
- Published
- 2025-09-21
- DOI
- https://doi.org/10.1016/j.bcp.2025.117361
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00